Key result
Intravenous midazolam in anaesthetized patients with coronary artery disease reduced mean arterial pressure by 17% and heart rate by 9% compared to baseline.
Why the study?
Does intravenous midazolam alter haemodynamic parameters in anaesthetized patients with coronary artery disease?
Does intravenous midazolam alter haemodynamic parameters in anaesthetized patients with coronary artery disease?
Intravenous midazolam produces favorable haemodynamic changes, including an increased endocardial viability ratio, supporting its use as an anesthetic supplement in patients with coronary artery disease.
Answers are grounded in this paper and cite their sources.
Should not yet change practice in CAD anesthesia; leaves open net effects on myocardial oxygen balance pending controlled trials.
The haemodynamic effects of midazolam 0.25 mg/kg administered intravenously were studied in eight anaesthetized patients suffering from coronary artery disease. Heart rate, systemic and pulmonary pressures, right atrial pressure, capillary pressure and cardiac output were measured 2, 5, 8 and 12 min after injection of midazolam and were compared with reference values collected before the commencement of the haemodynamic test. The cardiovascular condition of all the patients followed the same course after the injection of midazolam. The greatest variations were seen at the twelfth minute, with the exception of capillary pressure where the largest decrease was noted at the eighth minute. These variations, expressed as a percentage of the initial values, were: mean arterial pressure -17% (P less than 0.01); capillary pressure -23.5% (eight minute, P less than 0.01); heart rate - 9% (P less than 0.01); cardiac index -9% (P less than 0.01); systemic vascular resistance -12% (eighth minute, P less than 0.01). The stroke volume was well maintained (+0.1% NS). These haemodynamic variations were accompanied by a favourable evolution of the endocardial viability ratio (EVR), +12% (P less than 0.01). The slight tachycardia occasionally seen on induction of anaesthesia with midazolam was not seen in this group of patients. We conclude that these haemodynamic variations leading to an increase in EVR support the use of midazolam as a supplement to fentanyl anaesthesia for patients with coronary artery disease.
No takes yet. Share an insight, caveat, or question.
Massaut et al. (1983) studied Coronary artery disease (n=8). Midazolam vs. Baseline reference values was evaluated on Haemodynamic variations including mean arterial pressure and heart rate (p=<0.01). Intravenous midazolam in anaesthetized patients with coronary artery disease reduced mean arterial pressure by 17% and heart rate by 9% compared to baseline.
Synapse has enriched 10 related papers. Consider them for comparative context: